ATE283286T1 - Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion - Google Patents

Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion

Info

Publication number
ATE283286T1
ATE283286T1 AT01941783T AT01941783T ATE283286T1 AT E283286 T1 ATE283286 T1 AT E283286T1 AT 01941783 T AT01941783 T AT 01941783T AT 01941783 T AT01941783 T AT 01941783T AT E283286 T1 ATE283286 T1 AT E283286T1
Authority
AT
Austria
Prior art keywords
adnf
blends
memory function
improve learning
learning
Prior art date
Application number
AT01941783T
Other languages
English (en)
Inventor
Catherine Y Spong
Douglas Brenneman
Illana Gozes
Original Assignee
Us Gov Health & Human Serv
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Ramot filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE283286T1 publication Critical patent/ATE283286T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AT01941783T 2000-05-31 2001-05-31 Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion ATE283286T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20894400P 2000-05-31 2000-05-31
US26780501P 2001-02-08 2001-02-08
PCT/US2001/017758 WO2001092333A2 (en) 2000-05-31 2001-05-31 Use of adnf for enhancing learning and memory

Publications (1)

Publication Number Publication Date
ATE283286T1 true ATE283286T1 (de) 2004-12-15

Family

ID=26903662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941783T ATE283286T1 (de) 2000-05-31 2001-05-31 Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion

Country Status (12)

Country Link
US (2) US7427598B2 (de)
EP (1) EP1285000B1 (de)
JP (1) JP4440536B2 (de)
CN (1) CN1444600A (de)
AT (1) ATE283286T1 (de)
AU (2) AU2001275111B2 (de)
CA (1) CA2410735A1 (de)
DE (1) DE60107416T2 (de)
HK (1) HK1054947A1 (de)
MX (1) MXPA02011923A (de)
NZ (1) NZ522821A (de)
WO (1) WO2001092333A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US7384908B1 (en) 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
NZ522821A (en) * 2000-05-31 2004-08-27 Us Gov Health & Human Serv Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory: pre- and post-natal administration
AU2002335750A1 (en) * 2001-09-12 2003-03-24 Ramot At Tel-Aviv University Ltd. Neurotrophic components of the adnf i complex
CA2515603C (en) * 2003-02-10 2016-06-07 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
WO2005099741A1 (ja) * 2004-04-08 2005-10-27 Noevir Co., Ltd. 運動ニューロン疾患治療薬
CA2602893A1 (en) 2005-03-23 2006-09-28 Ramot At Tel Aviv University, Ltd. Use of adnf polypeptides for treating peripheral neurotoxicity
TWI303567B (en) * 2005-12-20 2008-12-01 Ind Tech Res Inst Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
WO2007096859A2 (en) * 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
AU2008291652A1 (en) * 2007-08-24 2009-03-05 Allon Therapeutics Inc. Neuroprotection using NAP-like and SAL-like peptide mimetics
WO2011021186A1 (en) 2009-08-17 2011-02-24 Ramot At Tel-Aviv University, Ltd. Nap alpha-aminoisobutyric acid analog with neuroprotective activity
EP2521919B1 (de) 2010-01-06 2015-03-04 Ramot at Tel Aviv University, Ltd. Verfahren zur diagnose und überwachung von schizophrenie und tauopathien
WO2012015910A2 (en) * 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
US20190192629A1 (en) * 2015-11-18 2019-06-27 Herantis Pharma Plc Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US6174862B1 (en) 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
CA2109098C (en) 1991-04-22 2005-08-09 Douglas E. Brenneman Activity-dependent neurotrophic factor
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
EP2172478A3 (de) 1997-02-07 2010-07-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aktivitätsabhängiger neurotrophischer Faktor III (ADNF III)
US6933277B2 (en) * 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
WO2001012654A2 (en) 1999-08-18 2001-02-22 Ramot University Authority For Applied Research & Industrial Development Ltd. Orally active peptides that prevent cell damage and death
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
NZ522821A (en) * 2000-05-31 2004-08-27 Us Gov Health & Human Serv Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory: pre- and post-natal administration

Also Published As

Publication number Publication date
JP4440536B2 (ja) 2010-03-24
NZ522821A (en) 2004-08-27
US20040048801A1 (en) 2004-03-11
DE60107416T2 (de) 2005-12-01
AU7511101A (en) 2001-12-11
US20090203615A1 (en) 2009-08-13
WO2001092333A3 (en) 2002-05-30
CA2410735A1 (en) 2001-12-06
DE60107416D1 (de) 2004-12-30
JP2003535105A (ja) 2003-11-25
EP1285000B1 (de) 2004-11-24
MXPA02011923A (es) 2004-09-06
AU2001275111B2 (en) 2006-07-06
CN1444600A (zh) 2003-09-24
HK1054947A1 (en) 2003-12-19
WO2001092333A2 (en) 2001-12-06
US7427598B2 (en) 2008-09-23
EP1285000A2 (de) 2003-02-26

Similar Documents

Publication Publication Date Title
ATE283286T1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
AU4185001A (en) Protein scaffolds for antibody mimics and other binding proteins
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DE69829293D1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
TW200611910A (en) Interferon-alpha polypeptides and conjugates
NO20030548D0 (no) Substratbehandling for rustfritt stål
DE69739375D1 (de) Verfahren zur regulierung der stickstoffmonoxid-erzeugung
DE50111031D1 (de) Copolymermischungen und ihre Verwendung als Additiv zur Verbesserung der Kaltfliesseigenschaften von Mitteldestillaten
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
WO2002046228A3 (en) Receptor for b. anthracis toxin
WO2005016233A3 (en) Botulinum neurotoxin b receptors and use thereof
DE60013093D1 (de) Methoden und kits zum sequenzieren von polypeptiden
TW200727909A (en) Enterokinesis promoting ingesta
ATE476447T1 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.
ATE319090T1 (de) Verwendung eines papillarfibroblast-spezifischen antikörpers als marker der hautqualität
ATE339683T1 (de) Verfahren zur detektion und konzentrationsbestimmung von schwefelfreien odoriermitteln in erd- oder brenngas
WO2005060998A3 (en) Methods of modulating cytokine activity; related reagents
DE69205005D1 (de) Verwendung von Atelokollagen als Festträger für die Fixierung eines spezifischen Fängers.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties